Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8N142

UPID:
PURA1_HUMAN

ALTERNATIVE NAMES:
Adenylosuccinate synthetase, basic isozyme; Adenylosuccinate synthetase, muscle isozyme; Adenylosuccinate synthetase-like 1; IMP--aspartate ligase 1

ALTERNATIVE UPACC:
Q8N142; Q86TT6; Q8N714

BACKGROUND:
The enzyme Adenylosuccinate synthetase isozyme 1, also known as IMP--aspartate ligase 1, is integral to the purine nucleotide cycle. This cycle is essential for maintaining balanced nucleotide levels in various tissues, contributing to key metabolic pathways like glycolysis. The enzyme's alternative names, such as Adenylosuccinate synthetase, basic isozyme, highlight its diverse roles.

THERAPEUTIC SIGNIFICANCE:
Given its association with Myopathy, distal, 5, a condition characterized by muscle weakness and atrophy starting in the lower limbs, the study of Adenylosuccinate synthetase isozyme 1 could lead to groundbreaking treatments. Exploring its function offers promising insights into combating muscular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.